Pcn192 Incidence of Febrile Neutropenia and Environmental Factors Observed With Optimal Receipt of Pegfilgrastim via on-Body Injector or Pre-Filled Syringe After Chemotherapy

Bonafede, Machaon; Hatfield, Mark; Lawrence, T.; Manjelievskaia, Janna; Evans, K.; Wing, V.; Shah, Neel

doi:10.1016/j.jval.2020.04.1670

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the European MONITOR-GCSF study 38 (2010-2013) reported that 13.4% of patients received biosimilar filgrastim on the day of chemotherapy compared to 56.4% within the guideline-recommended 24-72 h post-chemotherapy and 30.1% after this time window. A recent study by IBM Watson Health and Amgen found that, in the period from January 2017 to May 2018, 58.4% of reference pegfilgrastim administrations were "early" or same-day as chemotherapy 39 . While the pegfilgrastim OBI device enables clinicians to administer reference pegfilgrastim per label in the 24-72 h post-chemotherapy time window, failure and malfunction rates between 1.7 and 6.9% [40][41][42][43] have been reported.…”

Section: Discussionmentioning

confidence: 99%

Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv

MacDonald

McBride

Alrawashdh

et al. 2020

Journal of Medical Economics

View full text Add to dashboard Cite

Aims: In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer perspective, (2) simulated how savings enable, on a budget-neutral basis, expanded access to pegfilgrastim-cbqv, and (3) estimated the number-neededto-convert (NNC) to purchase one additional dose of pegfilgrastim-cbqv. Methods: In a hypothetical panel of 20,000 patients, we modeled cost-savings utilizing: two reference formulations (pre-filled syringe [PFS] and on-body injector [OBI]), three medication cost inputs (average sales price [ASP], wholesale acquisition cost [WAC], and an age-proportionate blended ASP/WAC rate), administration cost for injection (PFS) and device application (OBI), conversion rates of 10-100%, and 1-6 cycles of prophylaxis. Cost-savings were used to estimate additional doses of pegfilgrastim-cbqv that could be purchased and the NNC to purchase one additional dose. Results: Using ASP and 10% conversion from reference OBI to pegfilgrastim-cbqv, savings range from $326,744 (1 cycle) to $2.0M (6 cycles) which could provide 93-556 additional doses of pegfilgrastimcbqv, respectively; the NNC to purchase one additional dose of pegfilgrastim-cbqv ranges from 21.6 (1 cycle) down to 3.6 patients (6 cycles). The WAC model saves $41.1M per cycle and $246.7M over 6 cycles at 100% conversion from reference PFS which could provide 9,709-58,253 additional pegfilgrastim-cbqv doses; the NNC ranges from 2.1 (1 cycle) to 0.3 (6 cycles). Using the blended ASP/WAC rate, converting 50% from reference OBI to pegfilgrastim-cbqv would save $10.2M per cycle and $60.9M over 6 cycles providing 2,638-15,829 additional doses of pegfilgrastim-cbqv; NNCs are 3.8 (1 cycle) and 0.6 patients (6 cycles). Conclusions: Converting 20,000 patients from reference to pegfilgrastim-cbqv over 6 cycles can generate savings up to $246.7M, enough to purchase up to 58,253 additional doses of pegfilgrastim-cbqv. This simulation provides economic justification for prophylaxis with biosimilar pegfilgrastim-cbqv.

show abstract